Incidence and Outcomes Associated With Early Heart Failure Pharmacotherapy in Patients with Ongoing Cardiogenic Shock

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F14%3A43908087" target="_blank" >RIV/00216208:11120/14:43908087 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1097/CCM.0b013e31829f6242" target="_blank" >http://dx.doi.org/10.1097/CCM.0b013e31829f6242</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1097/CCM.0b013e31829f6242" target="_blank" >10.1097/CCM.0b013e31829f6242</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Incidence and Outcomes Associated With Early Heart Failure Pharmacotherapy in Patients with Ongoing Cardiogenic Shock

Popis výsledku v původním jazyce

Guidelines recommend beta-blockers and renin-angiotensin-aldosterone system blockers to improve long-term survival in hemodynamically stable myocardial infarction patients with a reduced left ventricular ejection fraction. The prevalence and outcomes associated with beta and renin-angiotensin-aldosterone system blocker therapy in patients with ongoing cardiogenic shock is unknown. In patients with cardiogenic shock lasting more than 24 hours enrolled in Tilarginine Acetate Injection in a Randomized International Study in Unstable Myocardial Infarction Patients With Cardiogenic Shock, we compared 30-day mortality in patients who received beta or renin-angiotensin-aldosterone system blockers within 24 hours of randomization with those who did not. The final study population included 240 patients. A total of 66 patients (27.5%) had either beta blocker or renin-angiotensin-aldosterone system blocker administered within the first 24 hours after the diagnosis of cardiogenic shock. Beta block

Název v anglickém jazyce

Incidence and Outcomes Associated With Early Heart Failure Pharmacotherapy in Patients with Ongoing Cardiogenic Shock

Popis výsledku anglicky

Guidelines recommend beta-blockers and renin-angiotensin-aldosterone system blockers to improve long-term survival in hemodynamically stable myocardial infarction patients with a reduced left ventricular ejection fraction. The prevalence and outcomes associated with beta and renin-angiotensin-aldosterone system blocker therapy in patients with ongoing cardiogenic shock is unknown. In patients with cardiogenic shock lasting more than 24 hours enrolled in Tilarginine Acetate Injection in a Randomized International Study in Unstable Myocardial Infarction Patients With Cardiogenic Shock, we compared 30-day mortality in patients who received beta or renin-angiotensin-aldosterone system blockers within 24 hours of randomization with those who did not. The final study population included 240 patients. A total of 66 patients (27.5%) had either beta blocker or renin-angiotensin-aldosterone system blocker administered within the first 24 hours after the diagnosis of cardiogenic shock. Beta block

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Critical Care Medicine

ISSN

0090-3493

e-ISSN

—

Svazek periodika

42

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

8

Strana od-do

281-288

Kód UT WoS článku

000329863400023

EID výsledku v databázi Scopus

—